Patented Medicines Regulations

3 (1) For the purposes of paragraphs 80(1)(a) and 80(2)(a) of the Act, information identifying the medicine shall indicate

• (a) the name and address of the patentee or former patentee and the address for correspondence in Canada;

• (b) whether the reporting patentee referred to in paragraph (a) is the patent holder, a person holding a licence other than a licence continued by subsection 11(1) of the Patent Act Amendment Act, 1992, or any other person referred to in the definition patentee in subsection 79(1) of the Act;

• (c) the generic name and brand name of the medicine;

• (d) whether the medicine is for human or veterinary use;

• (e) the therapeutic use of the medicine approved by the Minister of Health and Welfare;

• (f) the date on which the first notice of compliance was issued to the patentee or former patentee in respect of the medicine;

• (g) the drug identification number assigned to each strength and dosage form of the medicine under the Food and Drug Regulations;

• (h) the patent number of each invention of the patentee or former patentee pertaining to the medicine, the date on which each patent was granted and the date on which each patent will expire.

(2) The information required under subsection (1) shall be provided if

• (a) a notice of compliance has been issued in respect of the medicine; or

• (b) the medicine is being offered for sale in Canada.

(3) The information referred to in subsection (1) shall be provided within the earlier of

• (a) 30 days after the date on which the first notice of compliance is issued in respect of the medicine, and

• (b) 30 days after the date on which the medicine is first offered for sale in Canada.

(4) The information referred to in subsection (1) shall be up to date and any modification of that information shall be reported within 30 days after the modification.